新股预览:拨康视云-B(2592.HK)

光大新鸿基
Jun 24

背景公司是一间临床阶段眼科生物科技公司,致力于开发各种疗法。眼科是研究眼部结构、功能和疾病的医学分支。公司的历史可追溯至2015年集团成立之时。公司拥有两款核心产品(CBT-001 及CBT-009),均为自主开发。核心产品CBT-001 适用于治疗翼状胬肉(一种良性增生性眼表疾病),公司分别于2022 年6 月及2023 年9 月在美国及中国启动第3 期多地区临床试验(“多地区临床试验”)。概要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10